Media stories about Humanigen (NASDAQ:KBIO) have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Humanigen earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.5855653767232 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Humanigen (NASDAQ KBIO) opened at 2.19 on Monday. Humanigen has a one year low of $1.50 and a one year high of $4.75. The stock has a 50 day moving average price of $1.84 and a 200-day moving average price of $2.45. The company’s market capitalization is $32.80 million.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at

About Humanigen

Humanigen, Inc, formerly KaloBios Pharmaceuticals, Inc, is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems.

Insider Buying and Selling by Quarter for Humanigen (NASDAQ:KBIO)

Receive News & Stock Ratings for Humanigen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen Inc and related stocks with our FREE daily email newsletter.